A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

NCT03331731 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin Lymphoma

Interventions

DRUG: pembrolizumab

Sponsor

Peter MacCallum Cancer Centre, Australia